PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,608 | $2,908 | $5,377 | $4,991 |
| Gross Profit | -$1,608 | -$2,908 | -$5,377 | -$4,991 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,843 | $15,915 | $40,217 | $53,275 |
| G&A Expenses | $0 | $13,887 | $15,101 | $14,970 |
| SG&A Expenses | $13,966 | $13,887 | $15,101 | $14,970 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $23,809 | $27,147 | $56,515 | $68,832 |
| Operating Income | -$25,417 | -$32,083 | -$56,515 | -$72,550 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $683 | $32,376 | $2,720 | -$747 |
| Pre-Tax Income | -$24,734 | $293 | -$53,795 | -$73,297 |
| Tax Expense | -$1,246 | $521 | $2 | $3 |
| Net Income | -$23,488 | -$227 | -$53,797 | -$73,300 |
| % Margin | – | – | – | – |
| EPS | -4.62 | -0.1 | -22.7 | -36.55 |
| % Growth | -4,520% | 99.6% | 37.9% | – |
| EPS Diluted | -4.62 | -0.1 | -22.7 | -36.55 |
| Weighted Avg Shares Out | 5,080 | 3,102 | 2,369 | 2,006 |
| Weighted Avg Shares Out Dil | 5,080 | 3,102 | 2,369 | 2,006 |
| Supplemental Information | – | – | – | – |
| Interest Income | $259 | $4,453 | $13 | $889 |
| Interest Expense | $196 | $1,364 | $2,138 | $5,354 |
| Depreciation & Amortization | $1,608 | $2,908 | $5,377 | $4,991 |
| EBITDA | -$22,930 | -$3,460 | -$47,825 | -$66,382 |
| % Margin | – | – | – | – |